Skip to main content

FDA Approvals

Danyelza Receives FDA Approval for High-Risk Neuroblastoma in the Bone and Bone Marrow

Gavreto, a New RET Inhibitor, Now Approved for Thyroid Cancer with RET Fusions

Gavreto, RET Inhibitor, FDA Approved for Metastatic NSCLC with RET Fusions

Blenrep, First BCMA Antibody, Receives FDA Approval for Relapsed or Refractory Multiple Myeloma

FDA Approves Monjuvi for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Tecartus First CAR T-Cell Therapy FDA Approved for Patients with Mantle-Cell Lymphoma

Imbruvica (Ibrutinib) Receives Expanded Indication, in Combination with Rituximab, as First-Line Treatment for Chronic Lymphocytic Leukemia

Lisa A. Raedler, PhD, RPh

Mayzent (Siponimod) Approved for Relapsing Forms of Multiple Sclerosis, Including Active Secondary Progressive Disease

Lisa A. Raedler, PhD, RPh

Pemazyre (Pemigatinib) First Targeted Therapy FDA Approved for Cholangiocarcinoma with FGFR2 Biomarker

Loretta Fala

Tazverik (Tazemetostat) First FDA-Approved Treatment Specifically for Patients with Epithelioid Sarcoma

Loretta Fala

Page 15 of 53
Results 141 - 150 of 524